Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Other: Information Booklet
Other: TEAMWork App

First Posted Date: 2018-06-28

Last Posted Date: 2025-03-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 546

Registration Number: NCT03572374

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Consent and Follow-up), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent and Follow-up), Basking Ridge, New Jersey, United States
🇺🇸
Queens Cancer Center of Queens Hospital, Jamaica, New York, United States

and more 6 locations

A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

Phase 1

Active, not recruiting

Conditions: Lung Cancer

Interventions: Drug: Osimertinib
Drug: Platinum
Drug: Etoposide

First Posted Date: 2018-06-26

Last Posted Date: 2024-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT03567642

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 3 locations

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Daratumumab
Procedure: autologous hematopoietic cell transplantation

First Posted Date: 2018-06-14

Last Posted Date: 2025-04-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 41

Registration Number: NCT03556332

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Wake Forest University (Data Collection Only), Winston-Salem, North Carolina, United States
🇺🇸
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States

and more 9 locations

Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients

Recruiting

Conditions: Retinoblastoma
Pediatric Retinoblastoma

First Posted Date: 2018-06-06

Last Posted Date: 2024-07-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 75

Registration Number: NCT03546387

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Rucaparib
Radiation: Radiotherapy

First Posted Date: 2018-05-31

Last Posted Date: 2024-08-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 31

Registration Number: NCT03542175

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Norwalk Hospital, Norwalk, Connecticut, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States

and more 5 locations

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

Phase 1

Active, not recruiting

Conditions: Myeloid Diseases

Interventions: Drug: Antithymocyte globulin (Rabbit)
Drug: fludarabine
Radiation: total body irradiation
Drug: cyclophosphamide
Drug: Rituxan
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation

First Posted Date: 2018-05-22

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT03531736

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Phase 1

Completed

Conditions: Small Cell Lung Carcinoma
Small-cell Lung Cancer

Interventions: Drug: Olaparib Pill 50 mg
Drug: Olaparib Pill 100 mg
Drug: Olaparib Pill 150 mg
Drug: Olaparib Pill 200 mg
Drug: Olaparib Pill 250 mg
Drug: Olaparib Pill 300 mg
Radiation: Radiotherapy

First Posted Date: 2018-05-22

Last Posted Date: 2025-02-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 26

Registration Number: NCT03532880

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

and more 6 locations

Geriatric Communication Skills Training Program for Oncology Clinicians

Not Applicable

Completed

Conditions: Lymphoma
Bone Marrow Transplant
GU Cancer
GI Cancer

Interventions: Behavioral: The Consultation and Relational Empathy (CARE) questionnaire
Behavioral: Self-Efficacy Assessment
Behavioral: Consumer Assessment of Health Care Providers and Systems Program (CAHPS)
Behavioral: UCLA Geriatrics Attitudes Scale
Behavioral: Course Evaluations
Behavioral: Patient activation measure (PAM) scale

First Posted Date: 2018-05-21

Last Posted Date: 2024-02-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 88

Registration Number: NCT03530969

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer

Phase 2

Active, not recruiting

Conditions: Pancreatic Cancer

Interventions: Radiation: Hypofractionated ablative IMRT (HFA-IMRT)
Drug: capecitabine

First Posted Date: 2018-05-14

Last Posted Date: 2025-05-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 47

Registration Number: NCT03523312

Locations: 🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 5 locations

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Phase 1

Completed

Conditions: Cutaneous Squamous Cell Carcinoma
Head and Neck Cancer
Head and Neck Carcinoma
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Lenvatinib Pill
Drug: Cetuximab

First Posted Date: 2018-05-14

Last Posted Date: 2025-05-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT03524326

Locations: 🇺🇸
Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memoral Sloan Kettering Westchester, Harrison, New York, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy